Vicapsys Life Sciences, Inc. (VICP) stock
VICPOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Jan 10, 2025
$0.40+0.00 (0.00%)
Close on Oct 19, 2026Market cap $13.73MP/E –Yield –
Vicapsys Life Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vicapsys Life Sciences's operating income for the twelve months ending Sep 30, 2024 was -$1.11M. For fiscal 2023 it was -$1.05M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$1.05M | – |
| FY2022 | Dec 31, 2022 | -$984.79K | – |
| FY2021 | Dec 31, 2021 | -$336.87K | – |
| FY2020 | Dec 31, 2020 | -$765.84K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -$198.86K | – |
| Q2 FY2024 | Jun 30, 2024 | -$181.84K | – |
| Q1 FY2024 | Mar 31, 2024 | -$204.26K | – |
| Q4 FY2023 | Dec 31, 2023 | -$527.21K | – |
| Q3 FY2023 | Sep 30, 2023 | -$175.42K | – |
| Q2 FY2023 | Jun 30, 2023 | -$135.69K | – |
| Q1 FY2023 | Mar 31, 2023 | -$211.28K | – |
| Q4 FY2022 | Dec 31, 2022 | -$492.61K | – |
| Q3 FY2022 | Sep 30, 2022 | -$145.08K | – |
| Q2 FY2022 | Jun 30, 2022 | -$180.06K | – |
| Q1 FY2022 | Mar 31, 2022 | -$167.05K | – |
| Q4 FY2021 | Dec 31, 2021 | -$103.86K | – |
| Q3 FY2021 | Sep 30, 2021 | -$111.18K | – |
| Q2 FY2021 | Jun 30, 2021 | -$72.06K | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.77K | – |
| Q4 FY2020 | Dec 31, 2020 | -$80.55K | – |
| Q3 FY2020 | Sep 30, 2020 | -$89.22K | – |
| Q2 FY2020 | Jun 30, 2020 | -$231.62K | – |
| Q1 FY2020 | Mar 31, 2020 | -$364.46K | – |
See a number that looks wrong?